IBIO · iBio, Inc. · Insider Trading

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").

Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.

Vesting monthly on a pro rata basis over 36 months.

Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Shares purchased by MagicRoad SGPS, Unipessoal LDA, of which the Reporting Person is the sole director and shareholder, pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

The reported securities are held directly by MagicRoad SGPS, Unipessoal LDA ("MagicRoad"). The Reporting Person is the sole director and shareholder of MagicRoad and has sole voting and investment power of MagicRoad with respect to the shares held by MagicRoad.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest pro rata on a monthly basis over three years commencing on the date of the grant.

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2654 to $0.2671 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3100 to $0.3129 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3051 to $0.3068 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.